<div id="readability-page-1"><p>Goldman Sachs analyst Corinne Johnson maintained a Hold rating on Immunovant today and set a price target of $28.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Johnson covers the Healthcare sector, focusing on stocks such as Roivant Sciences, Rhythm Pharmaceuticals, and Halozyme. According to TipRanks, Johnson has an average return of <span>7.5%</span> and a 54.07% success rate on recommended stocks. </p> <p>In addition to Goldman Sachs, Immunovant also received a Hold from Truist Financial’s Danielle Brill in a report issued today. However, on the same day, LifeSci Capital maintained a Buy rating on Immunovant (NASDAQ: IMVT).</p></div>

IMVT

<p>Goldman Sachs analyst Corinne Johnson maintained a Hold rating on Immunovant with a $28.00 price target. Johnson, who covers the Healthcare sector, has a 7.5% average return and a 54.07% success rate. Truist Financial also issued a Hold rating, while LifeSci Capital maintained a Buy rating on Immunovant.</p>

Goldman Sachs Remains a Hold on Immunovant (IMVT)